Navigation Links
Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
Date:12/2/2009

SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through extraordinary times; markets are in turmoil and uncertainty is part of many businesses and industries. It turns out that the pharma industry has been relatively immune to the economic downturn, because illness doesn't take a vacation.

During the midst of the difficult times this year, the pharmaceutical giant Johnson & Johnson inaugurated an R&D center in Shanghai, the largest of its kind in Asia. A similar plan was laid down by its biotech counterpart Genzyme, who invested USD90 million in Beijing to construct the company's first ever research facility in Asia.

What has made pharma and biotech companies invest heavily in Asia?

Find out the answer at Asia Pharma R&D Leaders 2010. As the time is drawing near for the event, the world's industry leaders will be under one roof to provide solutions and case studies in the challenging areas of drug research and development.

This year's meeting will aim to improve understanding of how the Asian pharmaceutical market is changing. Meet with key pharma industry leaders to discuss and learn from their own experiences and hear from real-life case studies on operational, regulatory, and strategic challenges of outsourcing drug discovery work to Asia. This event also provides excellent networking opportunities by way of a speed networking sessions where attendees will exchange details and make new contacts, as well as our contact system, which will allow participants to arrange meetings and email conference with attendees, speakers and the press.

    An updated list of this year's highlighted topics:
    -- Partnering for innovation in Asia, new collaboration opportunities with
       big pharma
       Laurent Bertin, Vice President, R&D External Innovation, Sanofi-Aventis
       Hans-Jochiam Bohm, Head of Global Chemistry, Hoffman La-Roche
       Daniel Grant, Head of Strategic Alliances, Pfizer Australia
       Pierre Desmons, Director, Head of Development Partnerships,
        GlaxoSmithKline Biologicals
    -- Regulatory updates in China and how the FDA is verifying the quality
       of outsourced work
       Christopher Hickey, Country Director (China), U.S. Food and Drug
        Administration
    -- Successful stories of R&D operation management in Asia and Do's &
       Don'ts in outsourcing
       Steve Yang, Head of Research Asia Global R&D, Pfizer
       Lily Lee, Senior Vice President and Head of Pharmaceutical R&D Asia,
        Johnson & Johnson
       Li Chen, Chief Scientific Officer Roche R&D China, Roche
       Tony Zhang, Managing Director and Site Head of China, Eli Lilly Global
        R&D
       Canwen Jiang, Head of R&D Asia, Genzyme Corporation
       Kim Andersen, Vice President R&D, Lundbeck AS
       Samantha Du, CEO, Hutchison MediPharma
       Richard Wang, Director, Strategic Alliance and Collaboration for Asia,
        AstraZeneca
       Yoshiki Nishikawa, Director of Kobe Pharma Research Institute Nippon,
        Boehringer Ingelheim

Plus, the event sets up an effective platform for attendees to meet face to face with a variety of Asia's local CROs and leading clinical practitioners to discuss the specifics of outsourcing requirements.

An international audience consisting of senior-level pharma and biotech executives from the R&D, clinical development, business development, global market access, licensing, and regulatory affairs functions will be in attendance. For the full program and list of companies scheduled to attend, please visit the event website at http://www.aprdl.com.


    For more information on registration and sponsoring/exhibiting, please
contact:

     Daniel Chen
     Global Leaders Institute
     Phone: +86-21-3251-6046
     Email: daniel.chen@globaleaders.com

SOURCE Global Leaders Institute


'/>"/>
SOURCE Global Leaders Institute
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
2. Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service
3. Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
4. Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
5. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
6. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
7. Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance
8. KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals
9. Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
10. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
11. NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Research and Markets has announced ... Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, ... ... global market is projected to reach $15,737 million by 2022 from ... to 2022. Omic technologies segment accounted for more ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... Berkeley, CA (PRWEB) , ... January 19, 2017 ... ... the delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers ... Mail is a fully 21 CFR Part 11-compliant email client designed to provide ...
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, ... on enhancing productivity in aquaculture and a majority-owned subsidiary ... that it has completed the listing of its common ... equity subscription from Intrexon. "AquaBounty,s listing on ... will broaden our exposure to the U.S. markets as ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)... Market Research Future published a half cooked research report ... Security and Service Market is expected to grow over the CAGR ... Highlights: ... Mobile Biometric Security and Service Market is ... of authentication and security from unwanted cyber threats. The increasing use ...
Breaking Biology News(10 mins):